The serum levels of IL-6 and TNF-α were stimulated by rhein itself and in the rhein and atezolizumab group, leading to a conclusion that both rhein and atezolizumab—alone or in combination—are potent drugs for the treatment of 4T1 BC [94]. This evidence concerns the gene TNF and breast cancer.